Warren's bill would require that whenever drug companies enter into a settlement with the...
The global therapeutics market for Irritable Bowel Syndrome (IBS) is set to rise in value from $...
The Supreme Court (SCOTUS) decision that a federals appeals court wrongly overturned Teva...
The strong dollar and stiff competition for some products squeezed J&J in the fourth quarter and it missed Wall Street expectations for revenue, triggering a rare sell-off of its shares. The world's biggest maker of health care products did edge past profit forecasts and there were other bright spots, including a 10% jump in prescription drug sales and increasing use of medical care in the U.S.
Aetna has reached a deal with Gilead bringing discounts for Sovaldi and Harvoni, which have list prices of about $84,000 and $94,000, respectively, for a course of treatment. The amount of the discount wasn't disclosed.
Johnson & Johnson is working with a slew of organizations to speed up development of an Ebola vaccine, and the company said Friday that a European health organization awarded them $117 million.
AMRI has received a 10-year federal contract award from the NIH for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program, which is a component of the Blueprint Neurotherapeutics Network. AMRI has supported the NIH BPN since 2011, providing chemistry services and discovery technologies.
Evotec AG has announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process.
Moderna Therapeutics has announced a license and collaboration agreement with Merck for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).
Renewing a push for paid leave for workers, President Barack Obama will call on Congress, states and cities to pass measures to allow tens of millions of workers to earn up to a week of paid sick time a year, the White House said.
Elite Pharmaceuticals has announced the first shipments of generic Isradipine 2.5 mg and 5.0 mg capsules. Isradipine is a calcium channel blocker prescribed for hypertension.
Despite a lofty premium of more than 50% of NPS Pharmaceuticals’ (NPS) unaffected share price, Shire’s recent $5.2 billion acquisition of the company represents a fairly robust deal, says an analyst with research and consulting firm GlobalData.
Dendreon Corporation today announced that the company grew sales in four quarters successively, exceeded its revenue target for the first time ever, and achieved cash-flow break even in the fourth quarter (adjusted for non-recurring items), starting 2015 on a strong footing.
U.S. employers advertised the most job openings in nearly 14 years in November, the Labor Department said Tuesday. That suggests businesses are determined to keep adding staff because they are confident strong economic growth will create more demand for their goods and services.
Roche, Meiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Under the agreement, Roche obtains worldwide rights from both companies for development and commercialization with the exception of Japan, where Meiji will retain sole commercialization rights.
GlobalData: Rheumatoid Arthritis Treatment Market to be Transformed by Novel Drug and Biosimilar LaunchesJanuary 13, 2015 11:03 am | News | Comments
The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%, according to research and consulting firm GlobalData.
Shares of Pharmacyclics jumped Tuesday morning after the cancer treatment developer announced better-than-expected revenue forecasts for Imbruvica, a leukemia drug it sells with a Johnson & Johnson subsidiary.
Johnson & Johnson has licensed a potential treatment for inflammatory bowel diseases from a company developing therapies that alter interactions between the immune system and microbes in the body.
Merck is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today's hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer.
The pharmaceutical industry faces numerous issues on a day-to-day and yearly basis. Manufacturing, quality control, efficiences, budgets and regulations all must be met or exceeded. Here are ten industry critical issues, I feel the industry will be facing in the coming year.
Perrigo Company and Ferrara Candy Company announced today that Perrigo's Nutritionals division has signed a supply agreement with Ferrara to manufacture store brand gummy vitamins and dietary supplements to be sold at leading retailers across the United States.
The acquisition will expand Shire's portfolio of specialty drugs, medications for niche diseases and conditions that typically command much higher price tags than conventional medications. Shire's best-selling drugs currently include the attention deficit disorder drugs Vyvanse and Adderall XR.
Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.
Merck today will report on the ongoing execution of its multi-year, strategic initiative to sharpen its commercial and research and development (R&D) focus, redesign its operating model and reduce its cost base. In October 2013, Merck launched its global initiative to transform the company into a more competitive and innovative company and to build a platform for sustained future growth.
AmerisourceBergen and MWI Veterinary Supply, today announced that they have entered into a definitive merger agreement for AmerisourceBergen to acquire MWI Veterinary Supply (MWI), the leading animal health distribution company in the United States.
Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced study of a potential treatment for one of the most common forms of lung cancer. Company shares jumped Monday in premarket trading after the company said Opdivo met the main goal of a late-stage study by demonstrating better overall patient survival.
AbbVie is forecasting its 2015 profit will jump sharply from last year's, saying it expects "industry-leading growth," driven mainly by sales of its hot new hepatitis C treatment, Viekira.
Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK to Albany Molecular Research, Inc., and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million.
- Page 1